Positive News SentimentPositive News Wave Life Sciences Stock Price, News & Analysis (NASDAQ:WVE) $5.51 +0.20 (+3.77%) (As of 02:50 PM ET) Add Compare Share Share Today's Range$5.27▼$5.6950-Day Range$5.12▼$6.0252-Week Range$3.15▼$7.12Volume274,275 shsAverage Volume367,550 shsMarket Capitalization$545.77 millionP/E RatioN/ADividend YieldN/APrice Target$7.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Wave Life Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside30.1% Upside$7.40 Price TargetShort InterestBearish3.51% of Shares Sold ShortDividend StrengthN/ASustainability-0.58Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.60) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector495th out of 948 stocksPharmaceutical Preparations Industry235th out of 449 stocks 3.3 Analyst's Opinion Consensus RatingWave Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.40, Wave Life Sciences has a forecasted upside of 30.1% from its current price of $5.69.Amount of Analyst CoverageWave Life Sciences has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.51% of the outstanding shares of Wave Life Sciences have been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Wave Life Sciences has recently decreased by 3.06%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldWave Life Sciences does not currently pay a dividend.Dividend GrowthWave Life Sciences does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreWave Life Sciences has received a 77.37% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Wave Life Sciences is -0.58. Previous Next 2.7 News and Social Media Coverage News SentimentWave Life Sciences has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Wave Life Sciences this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Wave Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders31.10% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.91% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Wave Life Sciences are expected to decrease in the coming year, from ($0.60) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Wave Life Sciences is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Wave Life Sciences is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Wave Life Sciences Stock (NASDAQ:WVE)Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.Read More WVE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WVE Stock News HeadlinesNovember 22, 2023 | tmcnet.comWave Life Sciences to Present at 6?? Annual Evercore ISI HealthCONx ConferenceNovember 22, 2023 | finance.yahoo.comWave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx ConferenceDecember 1, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. November 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), Wave Life Sciences (WVE) and AC Immune SA (ACIU)November 11, 2023 | finance.yahoo.comWave Life Sciences Ltd. (NASDAQ:WVE) Q3 2023 Earnings Call TranscriptNovember 11, 2023 | markets.businessinsider.comWave Life Sciences: Buy Rating Based on Potential Pipeline Success and Key Catalysts for 2024November 11, 2023 | finance.yahoo.comAnalysts Just Made A Notable Upgrade To Their Wave Life Sciences Ltd. (NASDAQ:WVE) ForecastsNovember 9, 2023 | morningstar.comWAVE Life Sciences Ltd WVEDecember 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 9, 2023 | finance.yahoo.comWave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 8, 2023 | msn.comWave Life Sciences Q3 2023 Earnings PreviewNovember 3, 2023 | finance.yahoo.comWave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023October 27, 2023 | fool.comWave Life Sciences (NASDAQ: WVE)September 29, 2023 | finance.yahoo.comWave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?September 28, 2023 | finance.yahoo.comWave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D DaySeptember 25, 2023 | finance.yahoo.comWave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines ConferenceSeptember 18, 2023 | finance.yahoo.comWe Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business GrowthSeptember 6, 2023 | finance.yahoo.comWave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 5, 2023 | finance.yahoo.comWave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”August 23, 2023 | finance.yahoo.comWAVE Life Sciences Ltd. Sees a 23% Stock Price Surge Over the Past Three MonthsAugust 10, 2023 | finance.yahoo.comWave Life Sciences Ltd. (NASDAQ:WVE) Q2 2023 Earnings Call TranscriptAugust 9, 2023 | markets.businessinsider.comTruist Financial Sticks to Their Buy Rating for Wave Life Sciences (WVE)August 8, 2023 | finance.yahoo.comAnalyst Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging HigherAugust 4, 2023 | markets.businessinsider.comRBC Capital Sticks to Its Hold Rating for Wave Life Sciences (WVE)August 4, 2023 | finance.yahoo.comWave Life Sciences Ltd.'s (NASDAQ:WVE) 42% Price Boost Is Out Of Tune With RevenuesJuly 27, 2023 | finance.yahoo.comWave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023July 6, 2023 | finance.yahoo.comWave Life Sciences (NASDAQ:WVE) shareholders have endured a 90% loss from investing in the stock five years agoSee More Headlines Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:WVE CUSIPN/A CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees250Year FoundedN/APrice Target and Rating Average Stock Price Target$7.40 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+39.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,820,000.00 Net Margins-99.39% Pretax Margin-99.39% Return on EquityN/A Return on Assets-40.29% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio1.59 Sales & Book Value Annual Sales$3.65 million Price / Sales144.10 Cash FlowN/A Price / Cash FlowN/A Book Value($0.41) per share Price / Book-12.95Miscellaneous Outstanding Shares99,050,000Free Float68,248,000Market Cap$525.96 million OptionableOptionable Beta-1.08 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Paul B. Bolno M.B.A. (Age 49)M.D., President, CEO & Director Comp: $1.1MMr. Kyle B. Moran CFA (Age 52)CFO & Principal Accounting Officer Comp: $677.87kDr. Chandra Vargeese Ph.D. (Age 62)CTO & Head of Platform Discovery Sciences Comp: $710.05kKate RauschHead of Investor RelationsMs. Linda Rockett J.D.General CounselDr. Christopher Francis Ph.D. (Age 45)Senior VP of Corporate Development & Head of Emerging Areas Comp: $493.13kMs. Daryn LewisSenior VP & Head of Human ResourcesDr. Sridhar Vaddeboina Ph.D.Senior Vice President of Chemistry, Manufacturing & ControlsMs. Anne-Marie Li-Kwai-CheungChief Development OfficerDr. Hsiu-Chiung Yang Ph.D.Senior Vice President of Translational MedicineMore ExecutivesKey CompetitorsSavaraNASDAQ:SVRATheravance BiopharmaNASDAQ:TBPHRAPT TherapeuticsNASDAQ:RAPTAvidity BiosciencesNASDAQ:RNATyra BiosciencesNASDAQ:TYRAView All CompetitorsInsiders & InstitutionsWalleye Capital LLCBought 148,960 shares on 11/21/2023Ownership: 0.150%Kynam Capital Management LPBought 7,480 shares on 11/15/2023Ownership: 3.970%Laurion Capital Management LPBought 42,662 shares on 11/15/2023Ownership: 0.880%The Manufacturers Life Insurance Company Bought 58,144 shares on 11/15/2023Ownership: 0.083%AQR Capital Management LLCBought 11,073 shares on 11/15/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions WVE Stock Analysis - Frequently Asked Questions Should I buy or sell Wave Life Sciences stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WVE shares. View WVE analyst ratings or view top-rated stocks. What is Wave Life Sciences' stock price target for 2024? 6 Wall Street research analysts have issued 1 year price objectives for Wave Life Sciences' shares. Their WVE share price targets range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $7.40 in the next year. This suggests a possible upside of 30.1% from the stock's current price. View analysts price targets for WVE or view top-rated stocks among Wall Street analysts. How have WVE shares performed in 2023? Wave Life Sciences' stock was trading at $7.00 on January 1st, 2023. Since then, WVE shares have decreased by 18.7% and is now trading at $5.69. View the best growth stocks for 2023 here. When is Wave Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our WVE earnings forecast. How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings data on Thursday, November, 9th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.21. The firm had revenue of $49.21 million for the quarter, compared to analysts' expectations of $28.81 million. What ETF holds Wave Life Sciences' stock ? iShares Neuroscience and Healthcare ETF holds 8,533 shares of WVE stock, representing 0.84% of its portfolio. What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO? 17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Wave Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN). Who are Wave Life Sciences' major shareholders? Wave Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include M28 Capital Management LP (7.11%), 683 Capital Management LLC (5.91%), Kynam Capital Management LP (3.97%), Adage Capital Partners GP L.L.C. (3.82%), Primecap Management Co. CA (3.82%) and Laurion Capital Management LP (0.88%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Paul Bolno and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of Wave Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:WVE) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Wave Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.